M
Marco Skardelly
Researcher at University of Tübingen
Publications - 82
Citations - 1627
Marco Skardelly is an academic researcher from University of Tübingen. The author has contributed to research in topics: Medicine & Glioma. The author has an hindex of 20, co-authored 69 publications receiving 1235 citations. Previous affiliations of Marco Skardelly include University of Stuttgart & Leipzig University.
Papers
More filters
Journal ArticleDOI
Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study.
Martin Ulrich Schuhmann,Detlef Stiller,Marco Skardelly,Johannes Bernarding,Petra M. Klinge,Amir Samii,Madjid Samii,Thomas Brinker +7 more
TL;DR: The study demonstrates the feasibility of volume selective 1H-MRS using the LCModel (Linear Combination of Model in vitro spectra of metabolites solutions) to monitor metabolic changes close to focal traumatic lesions and suggests how metabolic alterations can be differentiated in cause.
Journal ArticleDOI
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Azadeh Ebrahimi,Marco Skardelly,Irina Bonzheim,Ines Ott,Helmut Mühleisen,Franziska Eckert,Ghazaleh Tabatabai,Jens Schittenhelm +7 more
TL;DR: ATRX is a potential marker for prediction of IDH/H3F3A mutations and substratification of diffuse gliomas into survival relevant tumor groups and classification is of great importance for further clinical decision making especially concerning the therapeutic options available for diffusegliomas.
Journal ArticleDOI
Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Achim Seeger,Christian Braun,Marco Skardelly,Frank Paulsen,Jens Schittenhelm,Ulrike Ernemann,Sotirios Bisdas +6 more
TL;DR: In this paper, a forward discriminant analysis was undertaken to assess the power of the conjunction of MR perfusion techniques and MR spectroscopy (MRS) for improved differentiation between recurrent glioma and stable disease.
Journal ArticleDOI
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Felix Behling,Alonso Barrantes-Freer,Marco Skardelly,Maike Nieser,Arne Christians,Florian Stockhammer,Veit Rohde,Marcos Tatagiba,Christian Hartmann,Christine Stadelmann,Jens Schittenhelm +10 more
TL;DR: Routine screening for BRAF V600E mutations for glioblastomas WHO grade IV below the age of 30 is suggested, especially in gliOBlastomas with epithelioid features and in all rhabdoid meningiomasWHO grade III.
Journal ArticleDOI
In vivo visualization of prostate-specific membrane antigen in glioblastoma
Johannes Schwenck,Ghazaleh Tabatabai,Marco Skardelly,Gerhald Reischl,Rudi Beschorner,Bernd J. Pichler,Christian la Fougère +6 more
TL;DR: The expansion of nutrient vessels is an important factor in the growth of glioblastomas, which is one of the most vascularized tumours, and prostate-specific membrane antigen (PSMA) is overexpressed in the tumour vasculature of GBM.